List of articles with "Cambridge"

AX-158 Progress

AX-158 Progress

USA Cambridge Artax Biopharma Nck modulator AX-158
Transforming Data Storytelling

Transforming Data Storytelling

Cambridge England STC AI PowerPoint Add-In Data Storytelling
NXR and Emotiv Partnership

NXR and Emotiv Partnership

Cambridge United Kingdom Emotiv Neuro XR Emotional Mapping
H.I.G. Realty Acquires Cambridge Campus

H.I.G. Realty Acquires Cambridge Campus

H.I.G. Capital Cambridge United Kingdom Radio House
H.I.G. Realty's New Campus

H.I.G. Realty's New Campus

H.I.G. Capital Cambridge United Kingdom Radio House St. Andrew's House
H.I.G. Realty Expands

H.I.G. Realty Expands

H.I.G. Capital Cambridge United Kingdom Life Sciences
H.I.G. Realty Acquires Campus

H.I.G. Realty Acquires Campus

H.I.G. Capital Cambridge United Kingdom Radio House St. Andrew's House
H.I.G. Realty Acquisition

H.I.G. Realty Acquisition

H.I.G. Capital Cambridge United Kingdom Radio House St. Andrew's House
SmartKargo New Leaders

SmartKargo New Leaders

United States Cambridge SmartKargo Bill Tavares Rodney Small
New BCMA RNA Therapies

New BCMA RNA Therapies

USA Cambridge RNA Therapeutics Orna Therapeutics Simnova Biotech
2025 CIO Leadership Award

2025 CIO Leadership Award

United States Digital Transformation MIT Sloan Cambridge CIO Leadership
New Insights on Mitophagy

New Insights on Mitophagy

Cambridge United Kingdom Neurodegenerative Diseases Mission Therapeutics mitophagy
Great Awakening Crusade

Great Awakening Crusade

USA Cambridge William Tarbutton The Hoppers Great Awakening
LEQEMBI Approval

LEQEMBI Approval

United States Cambridge Eisai Leqembi Alzheimer's
Akebia Updates on Vafseo

Akebia Updates on Vafseo

United States Cambridge Vafseo Akebia Therapeutics CKD
Blueprint Medicines 2025 Outlook

Blueprint Medicines 2025 Outlook

United States Cambridge AYVAKIT Blueprint Medicines BLU-808
Regor's RGT-075 Results

Regor's RGT-075 Results

United States Cambridge Regor Therapeutics RGT-075 GLP-1 Agonist
Gadi Lachman's Resignation

Gadi Lachman's Resignation

USA Cambridge Healthcare Data TriNetX Gadi Lachman
Lachman Steps Down

Lachman Steps Down

USA Cambridge Healthcare Data TriNetX Gadi Lachman
Gadi Lachman Resigns

Gadi Lachman Resigns

USA Cambridge TriNetX Gadi Lachman Carlyle
Marengo at JPM Conference

Marengo at JPM Conference

United States Cambridge J.P. Morgan Marengo Therapeutics Invikafusp Alfa
Lachman Leaves TriNetX

Lachman Leaves TriNetX

USA Cambridge Healthcare Data TriNetX Gadi Lachman
DIOSynVax's New Advisory Committee

DIOSynVax's New Advisory Committee

Cambridge United Kingdom DIOSynVax Avian Flu Vaccine Development
DIOSynVax Advisory Board

DIOSynVax Advisory Board

USA Cambridge Influenza vaccine DIOSynVax Bird Flu Vaccine
Ketryx Milestone Year

Ketryx Milestone Year

USA Cambridge MedTech AI Innovations Ketryx
Aspyre® Lung and Trials

Aspyre® Lung and Trials

Cambridge United Kingdom Biofidelity CellCarta Aspyre Lung
UCB Partners with XtalPi

UCB Partners with XtalPi

USA Cambridge UCB XtalPi XtalFold
DIOSynVax Advisory Board

DIOSynVax Advisory Board

USA Cambridge Flu Vaccine Advisory Board DIOSynVax
Darktrace Acquires Cado

Darktrace Acquires Cado

Cambridge Cybersecurity United Kingdom Darktrace Cado Security
DIOSynVax Advisory Board

DIOSynVax Advisory Board

USA Cambridge Influenza vaccine Bird Flu DIOSynVax
Bryce Coté Joins Darktrace

Bryce Coté Joins Darktrace

Cambridge UK Chief Customer Officer Darktrace Bryce Coté
Myeloid at JP Morgan

Myeloid at JP Morgan

United States Cambridge JP Morgan Myeloid Therapeutics RNA Therapies
AI Trends for 2025

AI Trends for 2025

United States MIT Sloan Cambridge Artificial Intelligence Data Science
Invikafusp Alfa Gains FDA Status

Invikafusp Alfa Gains FDA Status

United States Cambridge FDA Fast Track Invikafusp Alfa Marengo
Agile Marketing Insights

Agile Marketing Insights

USA Cambridge Forrester AgileMarketing AgileSherpas
Inari's $144 Million Fundraise

Inari's $144 Million Fundraise

United States Cambridge Sustainable Food Inari Agriculture Seed Technology
ISM5411 Phase 1 Success

ISM5411 Phase 1 Success

United States Cambridge Inflammatory Bowel Disease Insilico Medicine ISM5411
Claure and Harvard Unite

Claure and Harvard Unite

United States Cambridge Marcelo Claure Bolivia 360 Growth Lab
2025 Breakthrough Technologies

2025 Breakthrough Technologies

United States Innovation Cambridge MIT Technology Breakthrough Technologies
NeuroSense Nasdaq Compliance

NeuroSense Nasdaq Compliance

United States Cambridge NeuroSense PrimeC Therapeutics
Alltrna Appoints CMO

Alltrna Appoints CMO

USA Cambridge Alltrna tRNA Dr. Nerissa Kreher
VBI's Sale to K2 Completed

VBI's Sale to K2 Completed

United States Cambridge VBI Vaccines K2 VBI Equity Trust Creditors Arrangement
Akebia Stock Options

Akebia Stock Options

United States Cambridge Akebia Therapeutics kidney disease Nasdaq AKBA
NeuroSense Partners for PrimeC

NeuroSense Partners for PrimeC

United States Cambridge NeuroSense PrimeC ALS Treatment
Invikafusp Alfa Phase 2

Invikafusp Alfa Phase 2

USA Cambridge Marengo Therapeutics Invikafusp Alfa STARt-001
NeuroSense Update

NeuroSense Update

United States Cambridge NeuroSense PrimeC ALS Treatment
Revolutionizing Software Development

Revolutionizing Software Development

USA Cambridge AI Platform Software Development Blitzy
Akebia at J.P. Morgan

Akebia at J.P. Morgan

United States Cambridge J.P. Morgan Vafseo Akebia Therapeutics
CIO Leadership in AI

CIO Leadership in AI

United States MIT Sloan Cambridge AI Leadership CIO Symposium
DA-1241 Phase 2a Results

DA-1241 Phase 2a Results

USA Cambridge MASH MetaVia DA-1241

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.